Last update 01 Jun 2025

GSK-2241658A

Overview

Basic Info

Drug Type
Shared antigen vaccine, Therapeutic vaccine, Genetically engineered subunit vaccine
Synonyms
GSK 2241658A Antigen-Specific Cancer Immunotherapeutic, GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic, NY-ESO-1 Antigen Specific Cancer Immunotherapeutic
+ [7]
Target
NY-ESO-1
Action
modulators
Mechanism
NY-ESO-1 modulators(Cancer/testis antigen 1 modulators)
Therapeutic Areas
NeoplasmsSkin and Musculoskeletal Diseases
Active Indication-
Inactive Indication
Metastatic melanoma
Originator Organization
GSK PlcGSK Plc
Active Organization-
Inactive Organization
GSK PlcGSK Plc
License Organization-
Drug Highest PhasePendingPhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with GSK-2241658A
NCT01213472
/ CompletedPhase 1
Study of GSK2241658A Antigen-Specific Cancer Immunotherapeutic in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma
100 Clinical Results associated with GSK-2241658A
Login to view more data
100 Translational Medicine associated with GSK-2241658A
Login to view more data
100 Patents (Medical) associated with GSK-2241658A
Login to view more data
100 Deals associated with GSK-2241658A
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic melanomaPhase 1
Australia
GSK PlcGSK Plc
31 Jan 2011
Metastatic melanomaPhase 1
Austria
GSK PlcGSK Plc
31 Jan 2011
Metastatic melanomaPhase 1
France
GSK PlcGSK Plc
31 Jan 2011
Metastatic melanomaPhase 1
Germany
GSK PlcGSK Plc
31 Jan 2011
Metastatic melanomaPhase 1
Italy
GSK PlcGSK Plc
31 Jan 2011
Metastatic melanomaPhase 1
Netherlands
GSK PlcGSK Plc
31 Jan 2011
Metastatic melanomaPhase 1
Switzerland
GSK PlcGSK Plc
31 Jan 2011
Metastatic melanomaPhase 1
United Kingdom
GSK PlcGSK Plc
31 Jan 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT01213472 (CTgov)
Phase 1
Melanoma
33
jcvaiuertg = nywqolrfnr goovifjcuv (qnwlvyfhhx, ralxweeawo - nmwsibuueo)
View more
-
09 Oct 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free